Viyash Scientific LtdNSE: VIYASH
Open the Viyash Scientific Ltd page
Follow Viyash Scientific LtdFree account. Get a note when Viyash Scientific Ltd files.
Q4 FY26 earnings call · May 25, 2026

Viyash Scientific Ltd Q4 FY26 Earnings Call: EBITDA Margin Expands 593 bps, Animal Health API Breaks Plateau

Cofacto ResearchPublished May 25, 20265 min read
Quick summary

Viyash Scientific Ltd held its Q4 FY26 earnings call on May 19, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Quarter Caps a Turnaround Year

  • Q4 FY26 total revenue of Rs.920 Cr— grew 19.1% YoY, with formulations at Rs.499 Cr (+28% YoY) and API at Rs.384 Cr (+5% YoY).
  • Q4 FY26 adjusted EBITDA of Rs.200 Cr— up 64% YoY, with margin expanding 593 bps to 21.7%; management described it as the strongest quarter in company history.
  • Q4 FY26 PAT turned around to Rs.66 Cr— from a loss of Rs.32 Cr in Q4 FY25.
  • FY26 full-year revenue of Rs.3,420 Cr— up 13.8% YoY; formulations at Rs.1,866 Cr (+18%), API at Rs.1,491 Cr (+8%).
  • FY26 adjusted EBITDA rose 59.6% to Rs.702 Cr— margin of 20.5% (up 590 bps); PAT surged over 14× to Rs.225 Cr from Rs.16 Cr in FY25.
  • Credit rating upgraded— long-term from A to AA-, short-term from A1 to A1+.

Animal Health Breaks Plateau; API Mix Improving

  • Animal health API run rate reached Rs.400 Cr in FY26— breaking a five-year plateau of ~Rs.250 Cr; management expects strong growth going forward.
  • Human health formulations shifted to complex productswith internal APIs, driving margin improvement; a potent lab for oncology product development has been initiated in R&D.
  • API business grew 7-8% in FY26— single-digit growth due to deliberate reduction in intermediate sales; within this, animal health API grew from Rs.350 Cr to Rs.400 Cr, and human health APIs grew double-digit.
  • CDMO revenue base of ~Rs.200-225 Cr in FY26— representing ~15% of total API top line (~Rs.1,500 Cr for FY26); relationships span 8-10 large innovator clients, most 10-15 years old.
  • Minority interest accounted for ~20% of PAT in Q4 FY26— driven by two majority-owned subsidiaries: Appco (US formulation, 60% owned, Rs.400-425 Cr annual revenue in FY26) and Spain subsidiary (60% owned, ~Rs.550 Cr annual revenue in FY26).

Margin Expansion Accelerates; Synergy Targets Raised

  • Q4 FY26 gross margin expanded 236 bps to 55.1%— management targets sustainable 55-60% range, driven by forward/backward integration and elimination of commodity products (which carry 30-35% gross margins).
  • Merger synergy target revised to Rs.125-150 Cr annualized— over the next 12-18 months (by early FY28), up from an initial Rs.50-60 Cr; current run-rate is tracking Rs.50-60 Cr annualized as of Q4 FY26.
  • EBITDA margin at 20.5% for FY26— above the guided 20% level; management plans significant R&D investment in FY27 and FY28 but expects to maintain current margin levels.
  • Effective tax rate guided at ~27% for FY27— declining to 26-27% from FY28 onward (down from old regime 35%), due to transition and one-time merger adjustments.
  • Geopolitical freight impact of Rs.1-2 Cr in Q4 FY26— raw material inventory adequate for 1-2 quarters; no material impact expected in Q1 FY27, with monitoring in Q2 FY27.
  • Margin volatility from raw materials not seen as significant risk— API business in regulatory markets allows cost pass-through; US formulation business restructured away from commodity exposure.

CDMO and Animal Health Pipelines Set for Multi-Year Wave

  • CDMO expected ~40% growth over 1-2 years (toward FY28)— from the current ~Rs.200-225 Cr base; formulation CDMO uses a partnership model with ~50-50% profit share (e.g., with Cipla, Dr. Reddy's).
  • 16-17 complex/high-potent API products under development— with profit-share or joint-development models; launches expected from FY29 through FY37.
  • 2-3 products with innovators expected to gain global approvals by end of FY27— built over the last 2 years; R&D labs for complex formulations coming online in Q1/Q2 FY27.
  • Animal health pipeline: 15-20 new API products from FY28 onward— with 5-6 large products expected to drive revenue from FY29; companion animal segment adds 7-8 new API products targeting patent expiries in FY30.
  • R&D team of ~250 scientists for API— including analytical and process; 55-60 scientists for human health formulation; management expanding animal health formulation R&D (headcount and CAPEX) as a key focus area for FY27.
  • Product development pipeline covers patents expiring up to 2035— regulatory approvals expected to start flowing from FY27, contributing to both top line and bottom line.

Rs.1,000 Cr EBITDA Target; Double-Digit API Growth in FY28

  • Management targets Rs.1,000 Cr EBITDA within 2-3 years (likely by FY29)— from the current run rate of ~Rs.800 Cr (achieved in Q4 FY26, exceeding the earlier FY27 target of Rs.800 Cr); an annual growth rate of ~15% indicated.
  • Management expects 15% growth rate possible over next 5 years (by FY31)— a detailed strategic plan to be presented in June 2026.
  • API business expected to deliver double-digit growth in FY28— supported by a large number of human health API approvals in FY27 and FY28, plus stepped-up animal health API approvals.
  • Depreciation: goodwill amortization to drop from ~Rs.100 Cr (FY26) to ~Rs.35 Cr (FY27)— becoming zero in H2 FY27; excluding amortization, depreciation run-rate expected similar to FY26 levels.
  • Key FY27 priorities— strengthening merger synergies, improving operational performance, efficient capital allocation, further debt reduction, and maximizing cash flow generation.
  • Receivable days increased by 5-6 days— due to revenue growth, but management considers this under control; operating discipline and cash conversion remain key priorities for FY27.
  • Management expressed confidence in the company's turnaround— acknowledging stakeholder patience over the past four to five years and reaffirming future potential.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page
Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.